Literature DB >> 21413580

Hyperendemicity of onchocerciasis in Ovia Northeast Local Government Area, Edo State, Nigeria.

F O Akinbo1, C E Okaka.   

Abstract

OBJECTIVE: The present study investigates the prevalence of onchocerciasis in 40 communities of the LGA and provides data, which could contribute towards the control programme of the disease in the local government Area, Edo state, Nigeria.
METHODS: A physician performed the skin examination and thereafter a skin biopsy taken and immersed in normal saline solution in the wells of micro titration plates and allowed to stand for 24 hours to allow microfilaria to emerge and then examined microscopically.
RESULTS: The prevalence of onchocerciasis was investigated amongst 40 communities in Ovia North-East LGA of Edo state, Nigeria. Of the 2020 subjects examined between March 2007 to April, 2008, 1674 (83%) of them harboured microfilaria in their skin tissues.Females had significantly (P < 0.001) higher prevalence than their male counterparts (93.1% vs 74.5%).
CONCLUSION: The hyperendemicity of the disease may however be due to poor distribution of ivermectin and non compliance on the part of the subjects taking the drug as some often complained about the side effects of ivermectin. The findings demonstrated hyperendemicity of infection and require urgent attention with ivermectin treatment and other control measures.

Entities:  

Mesh:

Year:  2010        PMID: 21413580     DOI: 10.4314/eajph.v7i1.64702

Source DB:  PubMed          Journal:  East Afr J Public Health        ISSN: 0856-8960


  1 in total

1.  Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria.

Authors:  Emily Griswold; Abel Eigege; Cephas Ityonzughul; Emmanuel Emukah; Emmanuel S Miri; Ifeoma Anagbogu; Yisa A Saka; Saliu Kadiri; Solomon Adelamo; Paul Ugbadamu; Clement Ikogho; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2018-06-21       Impact factor: 3.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.